Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells

Rebecca D. Pickard, Briohny H. Spencer, Amelia J. McFarland, Nijole Bernaitis, Andrew K. Davey, Anthony V. Perkins, Russ Chess-Williams, Catherine M. McDermott, Amanda Forbes, David Christie, Shailendra Anoopkumar-Dukie

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)

Abstract

Docetaxel was the first chemotherapeutic agent to increase survival time in patients with androgen-resistant prostate cancer. However, it provides only a modest increase in survival and is associated with significant toxicity. Therefore, there is an urgent need to identify potential adjunct therapies. Given the key role of autophagy in both tumour survival and chemoresistance, the impact of autophagy modulation on docetaxel toxicity was tested in vitro. PC-3 and LNCaP cells were pre-treated with the autophagy inhibitor 3-methyladenine (5 mM) and then exposed to various concentrations (0-100 μM) of docetaxel. Cytoxic effects of docetaxel were measured using resazurin reduction to resorufin, whilst autophagy and apoptosis was measured using monodansylcadaverine, annexin V and caspase-3, respectively. Docetaxel produced significant toxicity in PC-3 cells but was not toxic to LNCaP cells. Pre-treatment with the autophagy inhibitor, 3-methyladenine (5 mM) significantly protected PC-3 cells against docetaxel-induced cytotoxicity, increased autophagosome formation and apoptosis measured using monodansylcadaverine, annexin V and caspase-3 fluorescence, respectively. In contrast, 3-methyladenine was toxic by itself in LNCaP cells and also increased autophagic vesicle formation and apoptosis but did not influence docetaxel toxicity in these cells. These paradoxical effects of 3-methyladenine were largely independent of reactive oxygen species production. We show here that modulation of autophagy may influence docetaxel-induced toxicity in prostate cancer cells and these effects may differ between cell lines.

Original languageEnglish
Pages (from-to)793-799
Number of pages7
JournalNaunyn-Schmiedeberg's Archives of Pharmacology
Volume388
Issue number7
DOIs
Publication statusPublished - 22 Jul 2015

Fingerprint

docetaxel
Autophagy
Prostatic Neoplasms
Poisons
Annexin A5
Apoptosis
Caspase 3
Survival
3-methyladenine
Androgens

Cite this

Pickard, R. D., Spencer, B. H., McFarland, A. J., Bernaitis, N., Davey, A. K., Perkins, A. V., ... Anoopkumar-Dukie, S. (2015). Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells. Naunyn-Schmiedeberg's Archives of Pharmacology, 388(7), 793-799. https://doi.org/10.1007/s00210-015-1104-7
Pickard, Rebecca D. ; Spencer, Briohny H. ; McFarland, Amelia J. ; Bernaitis, Nijole ; Davey, Andrew K. ; Perkins, Anthony V. ; Chess-Williams, Russ ; McDermott, Catherine M. ; Forbes, Amanda ; Christie, David ; Anoopkumar-Dukie, Shailendra. / Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells. In: Naunyn-Schmiedeberg's Archives of Pharmacology. 2015 ; Vol. 388, No. 7. pp. 793-799.
@article{4519be57e2f44d8087c3021dde0a14d0,
title = "Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells",
abstract = "Docetaxel was the first chemotherapeutic agent to increase survival time in patients with androgen-resistant prostate cancer. However, it provides only a modest increase in survival and is associated with significant toxicity. Therefore, there is an urgent need to identify potential adjunct therapies. Given the key role of autophagy in both tumour survival and chemoresistance, the impact of autophagy modulation on docetaxel toxicity was tested in vitro. PC-3 and LNCaP cells were pre-treated with the autophagy inhibitor 3-methyladenine (5 mM) and then exposed to various concentrations (0-100 μM) of docetaxel. Cytoxic effects of docetaxel were measured using resazurin reduction to resorufin, whilst autophagy and apoptosis was measured using monodansylcadaverine, annexin V and caspase-3, respectively. Docetaxel produced significant toxicity in PC-3 cells but was not toxic to LNCaP cells. Pre-treatment with the autophagy inhibitor, 3-methyladenine (5 mM) significantly protected PC-3 cells against docetaxel-induced cytotoxicity, increased autophagosome formation and apoptosis measured using monodansylcadaverine, annexin V and caspase-3 fluorescence, respectively. In contrast, 3-methyladenine was toxic by itself in LNCaP cells and also increased autophagic vesicle formation and apoptosis but did not influence docetaxel toxicity in these cells. These paradoxical effects of 3-methyladenine were largely independent of reactive oxygen species production. We show here that modulation of autophagy may influence docetaxel-induced toxicity in prostate cancer cells and these effects may differ between cell lines.",
author = "Pickard, {Rebecca D.} and Spencer, {Briohny H.} and McFarland, {Amelia J.} and Nijole Bernaitis and Davey, {Andrew K.} and Perkins, {Anthony V.} and Russ Chess-Williams and McDermott, {Catherine M.} and Amanda Forbes and David Christie and Shailendra Anoopkumar-Dukie",
year = "2015",
month = "7",
day = "22",
doi = "10.1007/s00210-015-1104-7",
language = "English",
volume = "388",
pages = "793--799",
journal = "Naunyn-Schmiedeberg's Archives of Pharmacology",
issn = "0028-1298",
publisher = "Springer",
number = "7",

}

Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells. / Pickard, Rebecca D.; Spencer, Briohny H.; McFarland, Amelia J.; Bernaitis, Nijole; Davey, Andrew K.; Perkins, Anthony V.; Chess-Williams, Russ; McDermott, Catherine M.; Forbes, Amanda; Christie, David; Anoopkumar-Dukie, Shailendra.

In: Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 388, No. 7, 22.07.2015, p. 793-799.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells

AU - Pickard, Rebecca D.

AU - Spencer, Briohny H.

AU - McFarland, Amelia J.

AU - Bernaitis, Nijole

AU - Davey, Andrew K.

AU - Perkins, Anthony V.

AU - Chess-Williams, Russ

AU - McDermott, Catherine M.

AU - Forbes, Amanda

AU - Christie, David

AU - Anoopkumar-Dukie, Shailendra

PY - 2015/7/22

Y1 - 2015/7/22

N2 - Docetaxel was the first chemotherapeutic agent to increase survival time in patients with androgen-resistant prostate cancer. However, it provides only a modest increase in survival and is associated with significant toxicity. Therefore, there is an urgent need to identify potential adjunct therapies. Given the key role of autophagy in both tumour survival and chemoresistance, the impact of autophagy modulation on docetaxel toxicity was tested in vitro. PC-3 and LNCaP cells were pre-treated with the autophagy inhibitor 3-methyladenine (5 mM) and then exposed to various concentrations (0-100 μM) of docetaxel. Cytoxic effects of docetaxel were measured using resazurin reduction to resorufin, whilst autophagy and apoptosis was measured using monodansylcadaverine, annexin V and caspase-3, respectively. Docetaxel produced significant toxicity in PC-3 cells but was not toxic to LNCaP cells. Pre-treatment with the autophagy inhibitor, 3-methyladenine (5 mM) significantly protected PC-3 cells against docetaxel-induced cytotoxicity, increased autophagosome formation and apoptosis measured using monodansylcadaverine, annexin V and caspase-3 fluorescence, respectively. In contrast, 3-methyladenine was toxic by itself in LNCaP cells and also increased autophagic vesicle formation and apoptosis but did not influence docetaxel toxicity in these cells. These paradoxical effects of 3-methyladenine were largely independent of reactive oxygen species production. We show here that modulation of autophagy may influence docetaxel-induced toxicity in prostate cancer cells and these effects may differ between cell lines.

AB - Docetaxel was the first chemotherapeutic agent to increase survival time in patients with androgen-resistant prostate cancer. However, it provides only a modest increase in survival and is associated with significant toxicity. Therefore, there is an urgent need to identify potential adjunct therapies. Given the key role of autophagy in both tumour survival and chemoresistance, the impact of autophagy modulation on docetaxel toxicity was tested in vitro. PC-3 and LNCaP cells were pre-treated with the autophagy inhibitor 3-methyladenine (5 mM) and then exposed to various concentrations (0-100 μM) of docetaxel. Cytoxic effects of docetaxel were measured using resazurin reduction to resorufin, whilst autophagy and apoptosis was measured using monodansylcadaverine, annexin V and caspase-3, respectively. Docetaxel produced significant toxicity in PC-3 cells but was not toxic to LNCaP cells. Pre-treatment with the autophagy inhibitor, 3-methyladenine (5 mM) significantly protected PC-3 cells against docetaxel-induced cytotoxicity, increased autophagosome formation and apoptosis measured using monodansylcadaverine, annexin V and caspase-3 fluorescence, respectively. In contrast, 3-methyladenine was toxic by itself in LNCaP cells and also increased autophagic vesicle formation and apoptosis but did not influence docetaxel toxicity in these cells. These paradoxical effects of 3-methyladenine were largely independent of reactive oxygen species production. We show here that modulation of autophagy may influence docetaxel-induced toxicity in prostate cancer cells and these effects may differ between cell lines.

UR - http://www.scopus.com/inward/record.url?scp=84932192290&partnerID=8YFLogxK

U2 - 10.1007/s00210-015-1104-7

DO - 10.1007/s00210-015-1104-7

M3 - Article

VL - 388

SP - 793

EP - 799

JO - Naunyn-Schmiedeberg's Archives of Pharmacology

JF - Naunyn-Schmiedeberg's Archives of Pharmacology

SN - 0028-1298

IS - 7

ER -